The gap between what genetic science now knows about cancer risk and what most clinicians actually apply in practice may be one of the most consequential blind spots in modern oncology. A comprehensive narrative review published in Genes attempts to bridge that divide, synthesizing decades of progress in hereditary cancer genetics into a framework accessible across medical specialties — from primary care to surgical oncology.
The review highlights how next-generation sequencing has transformed cancer risk stratification from single-gene testing into routine multi-gene panel analysis, enabling clinicians to simultaneously assess dozens of high- and moderate-penetrance cancer susceptibility genes. Crucially, the authors draw attention to an underappreciated pipeline: tumor genomic profiling — performed primarily to guide treatment — frequently reveals germline mutations that would otherwise go undetected, creating downstream implications not only for patients but for their biological relatives. The review also addresses the expanding role of polygenic risk scores, which aggregate hundreds of common low-effect variants to quantify cancer susceptibility across populations, moving the field beyond rare monogenic syndromes toward a broader architecture of inherited risk.
This synthesis arrives at a moment when the evidence base has outpaced clinical implementation. Hereditary cancer programs are unevenly distributed, genetic counseling workforces are strained, and variant classification — the process of determining whether a mutation is truly pathogenic — remains inconsistently applied across institutions. The review's framing of these issues as a cross-disciplinary communication failure is well-placed; oncologists managing treatment, surgeons planning prophylactic procedures, and primary care physicians coordinating long-term surveillance often operate from fragmented knowledge bases.
As a narrative review, this work synthesizes rather than generates new data, so it carries no independent statistical weight. Its value lies in conceptual integration. For health-conscious adults navigating family histories of cancer, the key takeaway is that germline testing indications have broadened substantially — and the information derived increasingly carries meaning beyond the individual tested.